Search results for "FIBROSIS"

showing 10 items of 901 documents

P017 C86/CD16 macrophages accumulate in the mucosa of B3 patients and could mediate EMT in Crohn’s disease

2020

Abstract Background Macrophages contribute to fibrosis through the release of different mediators and the pattern of secretion may vary according to their phenotype. Methods The aim of the present study is to analyse the pattern of expression of macrophages, of EMT-related genes and cytokines in surgical resections from Crohn’s disease (CD, n = 43) patients which were categorised according to Montreal classification (B2 or B3); unaffected mucosa of patients with ileocecal cancer was used as control (n = 20). mRNA was isolated from intestinal samples and the expression of macrophage, EMT markers and cytokines were analysed by RT-PCR. PBMCS were isolated from healthy donors and treated during…

Crohn's diseasebiologyU937 cellbusiness.industrymedicine.medical_treatmentGastroenterologyCancerMucous membraneVimentinGeneral Medicinemedicine.diseaseCytokinemedicine.anatomical_structureFibrosismedicinebiology.proteinCancer researchbusinessInterleukin 4Journal of Crohn's and Colitis
researchProduct

P051 Macrophages as a source of Notch Ligands in Crohn’s disease: implications in fibrosis

2021

Abstract Background Fibrosis constitute the main complications associated to Crohn’s disease (CD). Notch signalling has been implicated in lung, kidney, liver and cardiac fibrosis. Macrophages contribute to fibrosis through the release of different mediators and the pattern of secretion may vary according to their microenvironment. The aim of the present study is to analyze the role of Notch ligands derived from macrophages in the complications of CD. Methods We have analyzed: the mRNA expression of cytokines and Notch ligands in CD patients with fistulizing and stenting pattern, the mRNA and protein expression of macrophage markers and Notch ligands in macrophages treated with the main cyt…

Crohn's diseasebiologybusiness.industrymedicine.medical_treatmentGastroenterologyVimentinGeneral Medicinemedicine.diseaseInterleukin 10CytokineFibrosismedicinebiology.proteinCancer researchSignal transductionInterleukin 6businessInterleukin 4Journal of Crohn's and Colitis
researchProduct

P056 Crohn’s Disease associated fibrosis modulates the expression of collagen receptors

2021

Abstract Background Crohn’s Disease (CD) patients often develop stenotic complications as immunomodulatory treatments do not prevent the fibrogenic response in the affected tissues, where a dysregulated activation of stromal cells provokes an excessive deposition of extracellular matrix (ECM). Recent evidences support the notion that local cells can sense the consequent alterations in tissue structure and rigidity through receptors that respond to some ECM components, and this may perpetuate the fibrogenic process even in the absence of inflammation. We aim to analyse the relevance of these signalling pathways in the fibrotic process associated to CD. Methods We obtained fibrotic ileal tiss…

Crohn's diseasebiologybusiness.industrymedicine.medical_treatmentIntegrinGastroenterologyInflammationGeneral Medicinemedicine.diseaseCollagen receptorExtracellular matrixCytokineFibrosismedicineCancer researchbiology.proteinmedicine.symptomSignal transductionbusinessJournal of Crohn's and Colitis
researchProduct

DOP21 Role of P2X7 in intestinal fibrosis and inflammasome activation: Relevance in Crohn′s Disease

2021

Abstract Background Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract whose etiology is unknown. CD is associated with complications such as fibrosis or fistula, which cannot be pharmacologically reversed, requiring repeated surgery. Although a profibrotic effect of the P2X7 receptor has been described in some scenarios such as lung, heart and liver, its role in intestinal fibrosis has not been analysed yet. Given the crosstalk between fibrosis and inflammasome, we aim to analyze the relevance of P2X7 in intestinal fibrosis and inflammasome activation. Methods Surgical intestinal resections of CD patients and healthy ileum of carcinoma patients were obtai…

Crohn's diseasebusiness.industryGastroenterologyCaspase 1InflammasomeGeneral Medicinemedicine.diseaseInflammatory bowel diseaseFibrosisImmunologymedicineInterleukin 18ColitisbusinessIrritable bowel syndromemedicine.drugJournal of Crohn's and Colitis
researchProduct

P046 Vitamin D decreases PDIA3 and prevents the enhanced migration of fibroblasts from stricturing Crohn’s disease

2020

Abstract Background Fibrosis is a common complication in Crohn’s disease (CD) patients and fibroblasts play an important role in the fibrogenic process. Low vitamin D (VD) levels and a defective VD-signalling pathway have been reported in CD. VD signals through both vitamin D receptor (VDR) and protein disulfide-isomerase A3 (PDIA3) and we have previously demonstrated that VDR protein levels are reduced in fibroblasts isolated from CD patients and that VD increased VDR expression in these cells (A-2080; ECCO 2019). We aim to analyse here the effect of VD on both PDIA3 protein levels and migration in CD fibroblasts. Methods We used intestinal fibroblasts isolated from surgical resections of …

Crohn's diseasebusiness.industryGastroenterologyMucous membraneGeneral MedicinePDIA3medicine.diseasemedicine.anatomical_structureVitamin D3 ReceptorFibrosismedicineCancer researchVitamin D and neurologybusinessProtein disulfide-isomeraseHormoneJournal of Crohn's and Colitis
researchProduct

Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia.

1984

The L1210 tumor system was used in vitro and in vivo in comparative studies with activated cyclophosphamide analogs, cyclophosphamide and phosphoramide mustard. All the above compounds gave substantial cell kills (5 logs) of L1210 in vivo at doses that were non-toxic, but slight differences were noted. ASTA Z 7557 had a slight advantage in cure rate over cyclophosphamide when these drugs were given i.v. or i.p. to early tumor (i.p.). However, cyclophosphamide had the advantage in cure rate when drug administration was i.v. to advanced tumor. At equimolar concentrations in vitro ASTA Z 7557 was more cytotoxic than either phosphoramide mustard or acrolein. In vivo, the activated cyclophospham…

CyclophosphamideCell SurvivalPharmacologychemistry.chemical_compoundMiceFibrosisIn vivomedicineAnimalsPharmacology (medical)Clonogenic assayLeukemia L1210CyclophosphamideTumor Stem Cell AssayPharmacologyMice Inbred BALB CDose-Response Relationship Drugbusiness.industryAcroleinTumor Stem Cell Assaymedicine.diseasePhosphoramide MustardIn vitroOncologychemistryMice Inbred DBAPhosphoramide Mustardsbusinessmedicine.drugInvestigational new drugs
researchProduct

Roflumilast Prevents the Metabolic Effects of Bleomycin-Induced Fibrosis in a Murine Model

2015

Fibrotic remodeling is a process common to chronic lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, acute respiratory distress syndrome and asthma. Based on preclinical studies phosphodiesterase 4 (PDE4) inhibitors may exhibit beneficial anti-inflammatory and anti-remodeling properties for the treatment of these respiratory disorders. Effects of PDE4 inhibitors on changes in the lung metabolome in models of pulmonary fibrotic remodeling have not yet been explored. This work studies the effects of the PDE4 inhibitor roflumilast on changes in the lung metabolome in the common murine model of bleomycin-induced lung fibrosis by nuclear magnetic resonance (…

CyclopropanesMalePathologymedicine.medical_specialtyMagnetic Resonance SpectroscopyPulmonary Fibrosislcsh:MedicineAminopyridinesPharmacologyBiologyBleomycinBleomycinMicechemistry.chemical_compoundFibrosisPulmonary fibrosismedicineMetabolomeAnimalsRespiratory systemlcsh:ScienceLungRoflumilastCOPDMultidisciplinaryLunglcsh:Rmedicine.diseaserespiratory tract diseasesMice Inbred C57BLDisease Models Animalmedicine.anatomical_structurechemistryBenzamidesMetabolomelcsh:QResearch Articlemedicine.drugPLOS ONE
researchProduct

Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the E…

2022

Background and aim: Direct Acting Antivirals(DAAs) achieve the highest rate of sustained viral re- sponse(SVR) in patients with genotype-1b(G1b) Hepatitis C virus(HCV) infection. Reducing treatment du- ration can simplify the management and improve adherence of therapy. Patients and methods: The study evaluates the efficacy of 8 weeks of elbasvir/grazoprevir regimen in 75 treatment-naïve(TN), G1b patients with mild-moderate fibrosis(Liver Stiffness by Fibroscan®< 9.0 kPa). Viral load(VL) has been evaluated by Roche TaqMan RT-PCR(LLOQ < 15 IU/ml). Results: Mean age was 61.0 ±14.2 years, 44% were male, mean LS by Fibroscan®was 6.1 ±1.8 kPa. Twenty-eight patients(37.3%) had an HOMA > …

CyclopropanesMalemedicine.medical_specialtyElbasvirGenotypeHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologyAntiviral AgentsSettore MED/07Insulin resistanceFibrosisInternal medicineQuinoxalinesRibavirinmedicineElbasvir GrazoprevirHumansAgedBenzofuransSulfonamidesHepatologybusiness.industryGastroenterologyImidazolesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseAmidesHepatitis CSustained virological responseRegimenGlucoseGrazoprevirHCVRNADrug Therapy CombinationFemaleCarbamatesSafetyLiver stiffnessbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury

2009

Mandarin translation of abstract Background and purpose:  The effects of a phosphodiesterase 4 (PDE4) inhibitor, roflumilast, on bleomycin-induced lung injury were explored in ‘preventive’ and ‘therapeutic’ protocols and compared with glucocorticoids. Experimental approach:  Roflumilast (1 and 5 mg·kg−1·d−1, p.o.) or dexamethasone (2.5 mg·kg−1·d−1, p.o.) was given to C57Bl/6J mice from day 1 to 14 (preventive) or day 7 to 21 (therapeutic) after intratracheal bleomycin (3.75 U·kg−1). In Wistar rats, roflumilast (1 mg·kg−1·d−1, p.o.) was compared with methylprednisolone (10 mg·kg−1·d−1, p.o.) from day 1 to 21 (preventive) or from day 10 to 21 (therapeutic), following intratracheal instillatio…

CyclopropanesMalemedicine.medical_specialtyPhosphodiesterase InhibitorsPulmonary FibrosisAminopyridinesLung injuryBiologyBleomycinBronchoalveolar Lavagechemistry.chemical_compoundBleomycinMiceFibrosisRight ventricular hypertrophyInternal medicinePulmonary fibrosismedicineAnimalsRats WistarLungDexamethasoneRoflumilastPharmacologymedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionLung Injuryrespiratory systemmedicine.diseaseResearch Papersrespiratory tract diseasesRatsMice Inbred C57BLDisease Models AnimalBronchoalveolar lavageEndocrinologychemistryBenzamidesPhosphodiesterase 4 InhibitorsBronchoalveolar Lavage Fluidmedicine.drug
researchProduct

The role of attachment patterns and family functioning on psychophysical well-being in children with Cystic Fibrosis Preliminary Results

2013

(1) Introduction Scientific literature evidences a link between the quality of personal relationships and health status: the attachment style has a role on health and growth outcomes (Feeney, 2000) especially in chronic illness representing a threatening situation (Ciechanowski, 2003). Cystic fibrosis (CF) is a chronic genetic condition compromising the exocrine glands functioning and requiring intensive daily therapies (White et al., 2009). In pediatric condition, infant-mother relationship constituted an important element for nutritional status in CF children (Simmons et al., 1995; Anthony et al. 1999) which is one of the major factors contributing to improve longevity and quality of life…

Cystic Fibrosis attachment psychophysical well-being
researchProduct